TransCode Therapeutics (RNAZ) Proxy filing summary

Executive summary

• Entered into a Standby Equity Purchase Agreement (SEPA) with YA II PN, LTD, allowing up to $14 million in common stock sales at the company's discretion, subject to conditions and limitations.

• Secured up to $6 million in pre-paid advances via convertible promissory notes, with $1 million available upon filing the 2025 10-K and $5 million upon shareholder and Nasdaq approval.

• Financing structure extends operational runway into late 2027/early 2028, supporting ongoing clinical trials and strategic initiatives.

• Convertible notes accrue 5% annual interest, are issued at a 5% discount, and are convertible into common stock at variable prices based on market VWAP, subject to a floor price.

• The SEPA and related agreements include customary representations, warranties, covenants, and indemnification provisions.

Voting matters and shareholder proposals

• Shareholder approval is required to issue shares under the SEPA in excess of the Exchange Cap (19.99% of outstanding shares), with a proxy statement to be filed for this purpose.

• The board will recommend approval of the SEPA and related share issuances at a special or annual meeting within 180 days of the agreement.

Board of directors and corporate governance

• Board approval is required for all transactions under the SEPA and related agreements, and resolutions must remain in effect at each closing.

• Information about directors and executive officers is available in the company's prior proxy statement and current filings.